HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Wylam, M. E. Articles by Anderson, P. M. Search for Related Content PubMed PubMed Citation Articles by Wylam, M. E. Articles by Anderson, P. M.

Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis

Dept of Internal Medicine and Paediatrics, Mayo Clinic College of Medicine, Rochester, MN, USA.

CORRESPONDENCE: M. E. Wylam, Mayo Clinic College of Medicine, Dept of Internal Medicine and Paediatrics, 200 First Street, S.W., Rochester, MN 55905, USA. Fax: 1 5072664372. E-mail: wylam.mark{at}mayo.edu

Keywords: Granulocyte-macrophage colony-stimulating factor, pulmonary alveolar proteinosis, surfactant

Received: May 17, 2005
Accepted November 3, 2005

Recently, granulocyte-macrophage colony-stimulating factor (GM-CSF) auto-antibodies have been found in many patients with pulmonary alveolar proteinosis (PAP). The present study reports a retrospective case series of patients who used aerosolised GM-CSF in the treatment of idiopathic PAP. Between 1999 and 2003, 12 patients elected to receive aerosolised GM-CSF (250 µg b.i.d. every other week) in lieu of whole-lung lavage or observation.

Patient characteristics, pulmonary function tests, arterial blood gas analysis, laboratory values and chest radiographs were extracted from the patient's medical records. Of the six patients tested, all had GM-CSF neutralising antibodies. Additionally, abnormalities in GM-CSF gene expression (one patient), receptor expression (two patients) and ability to upregulate adhesion molecules (one patient) were found.

All patients except one had a positive response (mean improvements in arterial oxygen tension, alveolar–arterial oxygen gradient, carbon monoxide diffusing capacity of the lung and forced vital capacity were 17.1 mmHg, 18.4 mmHg, 16.6% pred and 13.5% pred, respectively). Two patients made a complete recovery and were disease free 1 and 2 yrs after discontinuing treatment. Four patients showed complete response to both the initial course or when treated again for recurrence after discontinuation of treatment. One patient required dose escalation (500 µg b.i.d.) with complete response. GM-CSF was well tolerated without late toxicity after median (range) follow-up of 30.5 (3–68) months.

In conclusion, aerosolised granulocyte-macrophage colony-stimulating factor is safe and effective in treating pulmonary alveolar proteinosis providing an alternative to whole-lung lavage or subcutaneous granulocyte-macrophage colony-stimulating factor.

This article has been cited by other articles:

				G. Quezada, N. V. Koshkina, P. Zweidler-McKay, Z. Zhou, D. P. Kontoyiannis, and E. S. Kleinerman Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis Antimicrob. Agents Chemother., February 1, 2008; 52(2): 716 - 718. [Abstract] [Full Text] [PDF]

				M. E. Dexter, G. P. Cosgrove, and I. S. Douglas Managing a Rare Condition Presenting With Intractable Hypoxemic Respiratory Failure Chest, January 1, 2007; 131(1): 320 - 327. [Full Text] [PDF]